OriGene Logo

Customer Login

Checkout as a new customer

Creating an account has many benefits:

  • See order and shipping status
  • Track order history
  • Check out faster
Create an Account

TissueScan, Cancer Survey cDNA Array 384 - I

Be the first to review this product
SKU
CSRT102
381 samples covering 22 different cancers. Available in 2, 5, 10 identical plates.
  $2,120.00
In Stock*

Frequently Bought Together (4)

D11-18 Polink-1 HRP Polymer Detection for MOUSE and RABBIT antibodies on human tissue
18 ml
$420.00
D12-6 Polink-1 HRP Polymer Detection for MOUSE antibody on human or animal tissue (non-rodent)
6 ml
$250.00
HP205798 qSTAR qPCR primer pairs against Homo sapiens gene GAPDH 200 reactions
$150.00
MP205604 qSTAR qPCR primer pairs against Mus musculus gene Gapdh 200 reactions
$150.00
Specifications
Specifications
Product Data
TissueScan Type Cancer Survey
Array Name Cancer Survey cDNA Array 384 - I
Clinical Info
Diagnosis Category Multiple
Tissue Multiple
Shipping Ambient
Description 381 samples covering 22 different cancers. Available in 2, 5, 10 identical plates.
Reviews
Write Review
 
 
 
 
 

Be the first to review this product

Please note:
Only reviews with images are eligible for a $20/20€ Amazon gift card.
Reviews without images are eligible for a $10/10€ Amazon gift card.
For more details about the terms and conditions, please visit the promotion page.

Review image
Documents
Resources

file-alt Citations

The long non-coding RNA GHSROS reprograms prostate cancer cell lines toward a more aggressive phenotype
Thomas, Jeffery, Gahete et al
PeerJ (2021) 9, e10280 DOI: 10.7717/peerj.10280
Cited by 9
AI Summary: In this study, OriGene products, specifically the GHSROS expression plasmid (RC208374) and control vector (PS100001), were used to generate prostate cancer cell lines overexpressing GHSROS, enabling the authors to assess the functional role of this lncRNA in promoting aggressive cancer phenotypes.
FigureFigureFigure
Kallikrein family proteases KLK6 and KLK7 are potential early detection and diagnostic biomarkers for serous and papillary serous ovarian cancer subtypes
Tamir, Jag, Sarojini et al
J Ovarian Res (2014) 7 (1), 109 DOI: 10.1186/PREACCEPT-1736656869122663
AI Summary: OriGene’s TissueScan Cancer Survey Panel and OVC Panel I-IV were used for expression screening and validation of KLK6 and KLK7 biomarkers in various cancer types and ovarian cancer subtypes, supporting the identification of these genes as potential early detection markers for ovarian cancer.
Snippet: Poor quality specimens that produced no meaningful values after 40 cycles of qPCR were not included in the data processing steps. The TissueScan Cancer Survey Panel and OVC Panel I-IV (both from OriGene, Rockville, MD) were used as described by the manufacturer ... Cite SaveSaving
Conserved oncogenic behavior of the FAM83 family regulates MAPK signaling in human cancer
Cipriano, Miskimen, Bryson et al
Mol Cancer Res (2014) 12 (8), 1156-65 DOI: 10.1158/1541-7786.MCR-13-0289
AI Summary: OriGene’s TissueScan Cancer Survey Panel PCR array was used in this study to assess the expression levels of FAM83 family members across multiple human tumor types, contributing to the finding that several FAM83 proteins are frequently overexpressed in diverse cancers and are involved in MAPK signaling regulation.
FigureFigure
TACC3 deregulates the DNA damage response and confers sensitivity to radiation and PARP inhibition
Ha, Kim, Petersson et al
Oncogene (2014)
Cited by 24
AI Summary: OriGene’s TissueScan Cancer Survey cDNA array 96-I was used in this study to analyze TACC3 expression across 96 tissue samples from various solid tumors, facilitating the investigation of TACC3’s role in genomic instability and cancer sensitivity to radiation and PARP inhibition.
Snippet: TissueScan qPCR array. The human TissueScan Cancer Survey cDNA array 96-I (OriGene Technologies Inc, Rockville, MD, USA) consisted of 96 tissues from eight solid tumors (breast, colon, kidney, liver, lung, ovary, prostate and thyroid). ... Cite SaveSaving
Expression of polycomb targets predicts breast cancer prognosis
Jene-Sanz, Váraljai, Vilkova et al
Mol. Cell. Biol. (2013) 33 (19), 3951-61 DOI: 10.1128/MCB.00426-13
AI Summary: OriGene’s TissueScan Cancer Survey qPCR panel 384-1 (CSRT102) was used to analyze gene expression in breast ductal carcinoma samples, enabling the study’s investigation of EZH2 target gene expression and its correlation with breast cancer prognosis.
Snippet: isolated from breast ductal carcinomas were analyzed from the TissueScan Cancer Survey tissue quantitative PCR (qPCR) panel 384-1 (CSRT102;OriGene). ... 1.8 μg of the sample RNA was used for first-strand cDNA synthesis using the Superscript Vilo kit (Life Technologies).
FAM83B mediates EGFR- and RAS-driven oncogenic transformation
Cipriano, Graham, Miskimen et al
J. Clin. Invest. (2012) 122 (9), 3197-210 DOI: 10.1172/JCI60517
Cited by 5
AI Summary: OriGene's TissueScan Cancer Survey Panel 384-I was used to analyze FAM83B expression across 381 tissue samples from 17 different cancer types, helping to establish the association between elevated FAM83B levels and various cancers in the study.
Snippet: TissueScan Cancer Survey Panel 384—I, composed of 381 tissues covering 17 different cancers (Origene);
Showing 1-6 of 10 papers.
Powered by BizGenius
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.

Related Products